Yuki Tahata

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Hepatic recompensation in decompensated cirrhosis:Can decompensated cirrhosis be improved?

Hepatic recompensation in decompensated cirrhosis:Can decompensated cirrhosis be improved?

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

Published: May 13, 2026

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All-Cause Mortality After SVR in Advanced Chronic Hepatitis C.

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All-Cause Mortality After SVR in Advanced Chronic Hepatitis C.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 27, 2026

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Journal for immunotherapy of cancer

Published: March 16, 2026

Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.

Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.

Journal: Journal for immunotherapy of cancer

Published: March 16, 2026

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.

Journal: Journal of gastroenterology

Published: February 10, 2026

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: PloS one

Published: January 29, 2026

Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy.

Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy.

Journal: Hepatology communications

Published: October 31, 2025

Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 18, 2025

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 16, 2025

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.

Journal: PloS one

Published: October 14, 2025

Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy.

Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 29, 2025

Guidance for Liver Rehabilitation in Chronic Liver Disease.

Guidance for Liver Rehabilitation in Chronic Liver Disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 02, 2025

Showing 1-12 of 81

Last Updated: 09/26/2026